Novel small molecule drug candidates in under a week.
Our system uses an iterative building approach which derives the best candidate for virtually any disease target without the limitations of chemical libraries. It derives new chemical entities and optimizes their druglikeness properties to increase the likelihood it will pass pre-clinical and clinical testing. With new structures, there is less chance it is already being researched or patented. Our system can return these results within a week.
Our system uses an iterative building approach which derives the best candidate for virtually any disease target without the limitations of chemical libraries. It derives new chemical entities and optimizes their druglikeness properties to increase the likelihood it will pass pre-clinical and clinical testing. With new structures, there is less chance it is already being researched or patented. Our system can return these results within a week.
Location: United States, Michigan, Ann Arbor
Employees: 1-10
Founded date: 2017